Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 15 Jun 2026 for Definium Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Suzanne Louise Bruhn: trading record in brief
This profile gathers the share dealings of Suzanne Louise Bruhn across 3 companies, led by Travere Therapeutics, Inc., Definium Therapeutics, Inc. and Vigil Neuroscience, Inc. We count 11 filings; the first trade dates from 14 May 2021 and the latest from 11 June 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 15 June 2026: a share grant, in Definium Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Suzanne Louise Bruhn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
4,666 sharesCommon SharesSEC:0001193125-26-271154:0
4,000 shares0Common StockSEC:0001517790-26-000002:0
5,000 sharesCommon StockSEC:0000950170-25-102485:0
5,000 shares0Common StockSEC:0000950170-25-077274:0
6,500 shares0Common StockSEC:0001415889-25-013497:0
6,500 shares0Common StockSEC:0001415889-24-012845:0
13,671 shares0Common SharesSEC:0000899243-23-016417:0
4,500 shares0Common StockSEC:0001209191-23-030949:0
89,286 shares0Common SharesSEC:0000899243-22-028727:0
3,000 shares0Common StockSEC:0001209191-22-028686:0
3,000 shares0Common StockSEC:0001209191-21-033854:0
11 of 11 declarations
